NASDAQ:BRTX Biorestorative Therapies Q1 2026 Earnings Report $2.51 -0.09 (-3.46%) Closing price 09/24/2026 03:59 PM EasternExtended Trading$2.49 -0.02 (-0.72%) As of 09/24/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Biorestorative Therapies EPS ResultsActual EPS-$3.80Consensus EPS -$4.00Beat/MissBeat by +$0.20One Year Ago EPSN/ABiorestorative Therapies Revenue ResultsActual Revenue$0.02 millionExpected Revenue$0.31 millionBeat/MissMissed by -$288.83 thousandYoY Revenue GrowthN/ABiorestorative Therapies Announcement DetailsQuarterQ1 2026Date5/14/2026TimeBefore Market OpensConference Call DateThursday, May 14, 2026Conference Call Time4:00PM ETUpcoming EarningsBiorestorative Therapies' Q2 2026 earnings is estimated for Tuesday, September 29, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2026 Earnings ReportConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Biorestorative Therapies Earnings HeadlinesHead-To-Head Review: Biorestorative Therapies (NASDAQ:BRTX) versus Invivyd (NASDAQ:IVVD)September 19, 2026 | americanbankingnews.comBioRestorative Therapies consensus price target increased by 1,900% to $163.20September 16, 2026 | msn.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)BioRestorative Therapies Announces Reverse Stock SplitSeptember 2, 2026 | globenewswire.comBioRestorative Therapies Halts ExoCR and BioX ShipmentsAugust 14, 2026 | tipranks.comBioRestorative Therapies Overhauls Leadership and Board GovernanceJuly 18, 2026 | theglobeandmail.comSee More Biorestorative Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biorestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biorestorative Therapies and other key companies, straight to your email. Email Address About Biorestorative TherapiesBiorestorative Therapies (NASDAQ:BRTX) is a biotechnology company focused on developing regenerative medicine products using cell-based therapies. The company’s research programs are aimed primarily at treating musculoskeletal disorders and conditions associated with metabolic health. Its principal product candidate is BRTX-100, an autologous cell therapy being developed for painful degenerative disc disease. The treatment is designed to use a patient’s own bone marrow-derived cells, which are processed and expanded before being administered to the affected spinal disc. BioRestorative has advanced BRTX-100 through clinical development and has evaluated its safety and potential effectiveness in patients with chronic lower-back pain. The company is also developing ThermoStem, a cell therapy platform intended to generate brown adipose tissue for potential applications involving obesity and metabolic disorders. BioRestorative Therapies is based in the United States and conducts its development activities through research, clinical and regulatory programs. The company’s candidates remain subject to clinical testing and regulatory review, and their eventual availability and indications are not assured.View Biorestorative Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
